SOCIAL MEDIA

ProfilePicture.png

Twitter

IASLC EGFR, NSCLC, JTOCRR, LCSM: 22/06/2021 14:01:06


Horn et al. evaluated the content validity, clarity, and relevance of two patient reported outcomes for use in adults with #EGFR mutated #NSCLC https://t.co/ybwMnvvjjT @JTOonline @OncologyAdvance #JTOCRR #LCSM


Read more

ProfilePicture.png

Twitter

JTO & JTO CRR EGFR, NSCLC, JTOCRR, LCSM: 22/06/2021 14:02:16


Horn et al. evaluated the content validity, clarity, and relevance of two patient reported outcomes for use in adults with #EGFR mutated #NSCLC https://t.co/WNOP3sz5OX @IASLC @OncologyAdvance #JTOCRR #LCSM


Read more

ProfilePicture.png

Twitter

JanssenUS BREAKING, NSCLC, EGFR, lcsm: 22/06/2021 21:36:56


#BREAKING: Updated recommendation in V.5.2021 of the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesĀ®) @JNCCN non-small cell lung cancer (#NSCLC) with #EGFR exon 20 insertion mutations #lcsm https://t.co/iPHEvh1qt1


Read more

ProfilePicture.png

Twitter

NCI Systems Biology NCICSBC, NSCLC, immunotherapy, CIM21: 22/06/2021 12:07:03


Researchers @MoffittResearch #NCICSBC are studying the evolutionary and ecological dynamics that govern response and resistance of non-small cell lung cancer (#NSCLC) to #immunotherapy: https://t.co/9rlskdj0fA #CIM21


Read more

ProfilePicture.png

Twitter

Journal of Molecular Pathology MDPI Clinical_Trial, Lung_Cancer, immunotherapy, targeted_therapy, NSCLC: 23/06/2021 07:25:35


New paper šŸ‘‰Modern Challenges for Early-Phase #Clinical_Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell #Lung_Cancer #immunotherapy #targeted_therapy #NSCLC šŸ“Œhttps://t.co/tdORTNuKcK


Read more

ProfilePicture.png

Twitter

Research Square Preprints preprints: 22/06/2021 15:35:07


Causal Relationship between Postoperative Recurrence and PD-L1 and EGFR Mutations in NSCLC: A Retrospective Cohort Study #preprints


Read more

ProfilePicture.png

Twitter

Sandy Anderson : 22/06/2021 15:55:26


A truly integrated new study from board to bench to bedside by Franziska Michor and led by Kamrine Poels: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant NSCLC @NatureComms


Read more

ProfilePicture.png

Twitter

Oncology Publishers Feed Oncology, MedTwitter, MedEd: 22/06/2021 18:36:03


Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC More medical news at https://t.co/DUWSlWzJcW #Oncology #MedTwitter #MedEd


Read more

ProfilePicture.png

Twitter

ASCO Publications EGFR, RET, BRAF, lcsm, JCOPO: 22/06/2021 20:10:02


Using serial cfDNA @StephenVLiu et al. describe a case of divergent acquired resistance to osimertinib in #EGFR+ NSCLC mediated by #RET fusion and simultaneous #BRAF V600E mutation https://t.co/tJBTsL6xly #lcsm #JCOPO


Read more

ProfilePicture.png

Twitter

Targeted Oncology LCSM: 23/06/2021 00:00:42


Treatment of patients with EGFR-mutant nonā€“small cell lung cancer in the phase 3 ADAURA clinical trial resulted in practice-changing disease-free survival with tolerable safety. #LCSM


Read more

ProfilePicture.png

Twitter

Wellcome-home : 23/06/2021 00:15:28


(Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC) has been published on chineselgz -


Read more

ProfilePicture.png

Twitter

TYR Kinase papers : 23/06/2021 03:09:02


PKCĪ“-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs


Read more